The trends toward daily disposable and cosmetic-oriented contact lenses have spurred a surge in new product launches. Among these, particularly noteworthy is a niche market long dominated by international giants: silicone hydrogel lenses, with high oxygen permeability as their core advantage, are poised for a domestic breakthrough.

Otsuka Pharmaceutical announced that its anti-APRIL monoclonal antibody, sibeprenlimab (brand name: VOYXACT®), has been officially approved by the National Medical Products Administration (NMPA) of China for the treatment of adult patients with primary IgA nephropathy. As the first therapy selectively targeting APRIL (A Proliferation-Inducing Ligand), sibeprenlimab intervenes in disease progression at its source by blocking a key step in the generation of pathogenic IgA.

On July 7, GENESIGHT, an AI life sciences firm, closed a tens-of-millions-yuan seed round backed solely by lead investor Tsinghua Innovation Ventures with no financial advisor disclosed. Proceeds will fund its core data, modeling and clinical moat development, accelerate partnerships with top-tier Class A tertiary hospitals for commercial rollout, and advance its strategy of building a life science operating system rooted in cell-based world models. Having forged deep ties with multiple top hospitals to build closed-loop clinical datasets, GENESIGHT deploys its technology across three business verticals. It addresses a critical flaw plaguing conventional AI drug discovery: massive late-stage clinical losses, by forecasting human cellular drug efficacy pre-large-scale trials to rebuild pharmaceutical evaluation benchmarks.

Combined with high-speed acquisition and intelligent algorithms, the platform translates these "current fingerprints" into molecular identity and abundance information. Compared with detection principles that rely on complex optical, amplification, or labeling processes, solid-state nanopores enable direct measurement of the intrinsic physical properties of biological macromolecules, moving away from indirect biochemical reaction-based detection. This approach offers advantages including high sensitivity, fast speed, ease of miniaturization, compatibility with semiconductor processes, and scalability for array-based expansion.

Unlike the domestic endoscope innovations over the past decade, which have primarily focused on "functional endoscopy" directions such as fluorescence, narrow-band imaging, confocal imaging, and 3D imaging, Insy Medical has pursued innovation in product form. However, if wireless endoscopy is understood simply as cutting the cables to make it wireless, that perspective would be too narrow. The wireless endoscope embodies Insy Medical's three core foundational technology capabilities, each addressing real clinical pain points.

For now, Imunopharm continues to rely on its CDMO business for financial support. The prospectus indicates that during the reporting period, the company's operating revenue was primarily derived from the CDMO business conducted by its subsidiary, Cygenta Biotech, with services covering cell therapy products such as CAR-T, TCR-T, and CAR-NK.

At the research, development, and industrialization level, Gestala's Chengdu global headquarters and the world's first ultrasonic brain-computer interface super factory were officially commissioned in June, marking the company's transition from the laboratory phase to a new stage where engineering manufacturing and clinical translation proceed in parallel. Concurrently, with the inauguration of the Shanghai headquarters, the company has established a research, development, and innovation system driven by dual centers in Chengdu and Shanghai, creating the "Neolab" frontier laboratory in the field of brain sciences, and further strengthening its fundamental research capabilities at the intersection of brain sciences and artificial intelligence, as well as its ability to connect with global innovation resources.

What truly determines disease progression, drug response, and cell differentiation are often the subtle signals resulting from the cumulative effects of dozens of genes. Their expression levels are not prominent, and models based solely on superficial fitting will never capture these critical changes.

Soft Sense, a medical-grade flexible sensing platform firm, has closed a multi-million-US-dollar angel round with undisclosed investors and financial advisors. Backed by proprietary machine-washable flexible sensing technology, the company operates a fully self-developed platform covering four core application scenarios led by cardiovascular monitoring. The fundraising will accelerate the productization of its core technology, validate the commercial viability of its medical-grade washable wearable system, and build a proprietary medical data ecosystem. The global clinical wearable market is booming, yet mainstream products suffer a prevalent precision-usability tradeoff. Soft Sense’s bottom-up technological innovation effectively addresses this longstanding industry gap.

It would be biased to attribute the success of Jiangxi Biology solely to the policy dividends following the restructuring of a long-established state-owned enterprise. After all, the Wuhan, Lanzhou, and Changchun Institutes of Biological Products under Sinopharm Group have historically held approvals for TAT. In the face of competitors with equal or even stronger state-owned backgrounds, Jiangxi Biology has not been overwhelmed but has instead emerged as the dominant market leader.